Overview

  • Product nameAnti-Ikaros antibody
    See all Ikaros primary antibodies
  • Description
    Goat polyclonal to Ikaros
  • Tested applicationsSuitable for: WB, ICCmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Cow, Dog
  • Immunogen

    Synthetic peptide:

    C-DTPYDSSASYEKEN

    , corresponding to internal sequence amino acids 290-303 of Human Ikaros (NP_006051.1)

  • Positive control
    • MOLT4 lysate.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab106787 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 3 µg/ml. Predicted molecular weight: 65 kDa.
ICC Use a concentration of 2.5 - 3.8 µg/ml.

Target

  • FunctionTranscription regulator of hematopoietic cell differentiation (PubMed:17934067). Binds gamma-satellite DNA (PubMed:17135265, PubMed:19141594). Plays a role in the development of lymphocytes, B- and T-cells. Binds and activates the enhancer (delta-A element) of the CD3-delta gene. Repressor of the TDT (fikzfterminal deoxynucleotidyltransferase) gene during thymocyte differentiation. Regulates transcription through association with both HDAC-dependent and HDAC-independent complexes. Targets the 2 chromatin-remodeling complexes, NuRD and BAF (SWI/SNF), in a single complex (PYR complex), to the beta-globin locus in adult erythrocytes. Increases normal apoptosis in adult erythroid cells. Confers early temporal competence to retinal progenitor cells (RPCs) (By similarity). Function is isoform-specific and is modulated by dominant-negative inactive isoforms (PubMed:17135265, PubMed:17934067).
  • Tissue specificityAbundantly expressed in thymus, spleen and peripheral blood Leukocytes and lymph nodes. Lower expression in bone marrow and small intestine.
  • Involvement in diseaseDefects in IKZF1 are frequent occurrences (28.6%) in acute lymphoblasic leukemia (ALL). Such alterations or deletions lead to poor prognosis for ALL.
    Chromosomal aberrations involving IKZF1 are a cause of B-cell non-Hodgkin lymphomas (B-cell NHL). Translocation t(3;7)(q27;p12), with BCL6.
  • Sequence similaritiesBelongs to the Ikaros C2H2-type zinc-finger protein family.
    Contains 6 C2H2-type zinc fingers.
  • DomainThe N-terminal zinc-fingers 2 and 3 are required for DNA binding as well as for targeting IKFZ1 to pericentromeric heterochromatin.
    The C-terminal zinc-finger domain is required for dimerization.
  • Post-translational
    modifications
    Phosphorylation controls cell-cycle progression from late G(1) stage to S stage. Hyperphosphorylated during G2/M phase. Dephosphorylated state during late G(1) phase. Phosphorylation on Thr-140 is required for DNA and pericentromeric location during mitosis. CK2 is the main kinase, in vitro. GSK3 and CDK may also contribute to phosphorylation of the C-terminal serine and threonine residues. Phosphorylation on these C-terminal residues reduces the DNA-binding ability. Phosphorylation/dephosphorylation events on Ser-13 and Ser-295 regulate TDT expression during thymocyte differentiation. Dephosphorylation by protein phosphatase 1 regulates stability and pericentromeric heterochromatin location. Phosphorylated in both lymphoid and non-lymphoid tissues (By similarity). Phosphorylation at Ser-361 and Ser-364 downstream of SYK induces nuclear translocation.
    Sumoylated. Simulataneous sumoylation on the 2 sites results in a loss of both HDAC-dependent and HDAC-independent repression. Has no effect on pericentromeric heterochromatin location. Desumoylated by SENP1.
    Polyubiquitinated.
  • Cellular localizationCytoplasm; Nucleus. In resting lymphocytes, distributed diffusely throughout the nucleus. Localizes to pericentromeric heterochromatin in proliferating cells. This localization requires DNA binding which is regulated by phosphorylation / dephosphorylation events and Nucleus. In resting lymphocytes, distributed diffusely throughout the nucleus. Localizes to pericentromeric heterochromatin in proliferating cells. This localization requires DNA binding which is regulated by phosphorylation / dephosphorylation events (By similarity).
  • Information by UniProt
  • Database links
  • FormThere are 7 isoforms produced by alternative splicing.
  • Alternative names
    • CLL associated antigen KW 6 antibody
    • DNA-binding protein Ikaros antibody
    • hIk 1 antibody
    • Hs.54452 antibody
    • IK1 antibody
    • Ikaros (zinc finger protein) antibody
    • IKAROS antibody
    • IKAROS family zinc finger 1 (Ikaros) antibody
    • Ikaros family zinc finger protein 1 antibody
    • Ikzf1 antibody
    • IKZF1_HUMAN antibody
    • LYF1 antibody
    • Lymphoid transcription factor LyF-1 antibody
    • PRO0758 antibody
    • Zinc finger protein subfamily 1A 1 (Ikaros) antibody
    • Zinc finger protein subfamily 1A 1 antibody
    • Zinc finger protein, subfamily 1A, member 1 antibody
    • ZNFN1A1 antibody
    see all

Anti-Ikaros antibody images

  • Anti-Ikaros antibody (ab106787) at 1 µg/ml + MOLT4 lysate at 35 µg/ml

    Predicted band size : 65 kDa
  • 106787 (3.8µg/ml) staining of paraffin embedded Human Tonsil. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.

References for Anti-Ikaros antibody (ab106787)

ab106787 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab106787.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"